Logo for PCI Biotech Holding

PCI Biotech Investor Relations Material

Latest events

Logo for PCI Biotech Holding

Q4 2023 [NO]

PCI Biotech
Logo for PCI Biotech

Q4 2023 [NO]

14 Feb, 2024
Logo for PCI Biotech

Q2 2023

31 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from PCI Biotech Holding

Access all reports
Segment Data
Access more data
R&D expenses by
Category
Clinical studies
Pre-clinical studies
Patents
CMC and equipment
Expenses by
Financials
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's proprietary PCI technology targets tumors by non-invasively targeting PECAM-1 receptors on tumor blood vessels using light-activated prodrugs. It has been granted patent protection in the United States, European Union, and certain other jurisdictions for certain uses of its technologies and products.